A

Agenus
D

AGEN

3.11000
USD
0.26
(9.12%)
مغلق
حجم التداول
19,799
الربح لكل سهم
-5
العائد الربحي
-
P/E
-0
حجم السوق
78,710,496
أصول ذات صلة
ACI
ACI
-0.075
(-0.34%)
21.930 USD
AEE
AEE
1.460
(1.49%)
99.530 USD
A
AGNC
-0.07500
(-0.84%)
8.80500 USD
ARGX
ARGX
8.83
(1.38%)
648.74 USD
المزيد
الأخبار المقالات

العنوان: Agenus

القطاع: Healthcare
الصناعة: Biotechnology
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).